期刊
INTESTINAL RESEARCH
卷 18, 期 2, 页码 219-228出版社
KOREAN ASSOC STUDY INTESTINAL DISEASES
DOI: 10.5217/ir.2019.00037
关键词
Plasminogen activator inhibitor-1; Matrix metalloproteinase 9; Intestinal fibrosis; Crohn disease; 2,4,6-Trinitrobenzene sulfonic acid
资金
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) [17H05802]
- Japan Society for the Promotion of Science (JSPS) [19K017413]
- MEXT-Supported Program for the Strategic Research Foundation at Private University (Tokai University)
- Grants-in-Aid for Scientific Research [17H05802] Funding Source: KAKEN
Background/Aims: Intestinal fibrosis is a major complication of Crohn's disease (CD). The profibrotic protein transforming growth factor-beta (TGF-beta) has been considered to be critical for the induction of the fibrotic program. TGF-beta has the ability to induce not only the expression of extracellular matrix (ECM) including collagen, but also the production of plasminogen activator inhibitor-1 (PAI-1) that prevents enzymatic degradation of the ECM during the onset of fibrotic diseases. However, the significance of PAI-1 in the developing intestinal fibrosis has not been fully understood. In the present study, we examined the actual expression of PAI-1 in fibrotic legion of intestinal inflammation and its correlation with the abnormal ECM deposition. Methods: Chronic intestinal inflammation was induced in BALB/c mice using 8 repeated intrarectal injections of 2,4,6-trinitrobenzene sulfonic acid (TNBS). TM5275, a PAI-1 inhibitor, was orally administered as a carboxymethyl cellulose suspension each day for 2 weeks after the sixth TNBS injection. Results: Using a publicly available dataset (accession number, GSE75214) and TNBS-treated mice, we observed increases in PAI-1 transcripts at active fibrotic lesions in both patients with CD and mice with chronic intestinal inflammation. Oral administration of TM5275 immediately after the onset of intestinal fibrosis upregulated MMP-9 (matrix metalloproteinase 9) and decreased collagen accumulation, resulting in attenuation of the fibrogenesis in TNBS-treated mice. Conclusions: PAI-1-mediated fibrinolytic system facilitates collagen degradation suppression. Hence, PAI-1 inhibitor could be applied as an anti-fibrotic drug in CD treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据